SALT LAKE CITY, April 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter of 2014 following the close of market on Tuesday, May 6, 2014.
The Company also will host a conference call on Tuesday, May 6, 2014 at 4:30 p.m. ET to discuss the financial results. Participating on the call will be Peter Meldrum, president and chief executive officer; Mark Capone, president of Myriad Genetic Laboratories, Inc.; and James Evans, chief financial officer.
To listen to the call, interested parties may dial 800-667-8757 in the United States or +1 303-223-4377 for international callers. All callers will be asked to reference reservation number 21714202.
The conference call also will be available through a live webcast at www.myriad.com. A replay will be available two hours after the end of the call and for the following seven days, and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21714202.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk, are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.
Source:Myriad Genetics, Inc.